OTHERS_CITABLE
Number Crunching towards Molecular Barcoding
Molecules are the basic and most important players of life. Molecules are composed of atoms, and each molecule has two main specifications or inheritances that are structures, and in biomedical applications, biological function. This dichotomy can be compared to living organisms or humans whom possess genotype and phenotype. Each of the two main inherited elements contains a variety of feature classes and sub-categories. Due to ease of use, the scientific community focuses on elaborating the structure, rather than the function. Of course, this has also caused many debates on the priority of structure over the function or vice versa.
To better understand the features of the structure that could affect function and hence translate them into therapeutic or diagnostic applications, we may look at molecules through their properties that is an intermediary step in the process, which mostly includes the physico-chemical aspects.
http://ibj.pasteur.ac.ir/article-1-1924-en.pdf
2017-01-15
67
68
Soroush
Sardari
1
Drug Design and Bioinformatics Unit, Medical Biotechnology Dept., Pasteur Institute of Iran, Tehran 13164, Iran
AUTHOR
ORIGINAL_ARTICLE
Vaccine Candidates against Nontypeable Haemophilus influenzae: a Review
http://ibj.pasteur.ac.ir/article-1-1912-fa.pdf
2017-01-08
69
76
10.18869/acadpub.ibj.21.2.69
Vaccine Candidates against Nontypeable Haemophilus influenzae: a Review
Nonencapsulated, nontypeable Hemophilus influenzae (NTHi) remains an important cause of acute otitis and respiratory diseases in children and adults. NTHi bacteria are one of the major causes of respiratory tract infections, including acute otitis media, cystic fibrosis, and community-acquired pneumonia among children, especially in developing countries. The bacteria can also cause chronic diseases such as chronic bronchitis and chronic obstructive pulmonary disease in the lower respiratory tract of adults. Such bacteria express several outer membrane proteins, some of which have been studied as candidates for vaccine development. Due to the lack of effective vaccines as well as the spread and prevalence of NTHi worldwide, there is an urgent need to design and develop effective vaccine candidates against these strains.
http://ibj.pasteur.ac.ir/article-1-1912-en.pdf
2017-01-08
69
76
10.18869/acadpub.ibj.21.2.69
Vaccines
Chronic obstructive pulmonary disease
Haemophilus influenzae
Ava
Behrouzi
1
Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran
AUTHOR
Farzam
Vaziri
2
Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran
AUTHOR
Fatemeh
Rahimi-Jamnani
3
Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran
AUTHOR
Parviz
Afrough
4
Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran
AUTHOR
Mohammad
Rahbar
5
Department of Microbiology, Reference Health Laboratories Research Center, Ministry of Health and Medical Education, Tehran, Iran
AUTHOR
Fereshteh
Satarian
6
Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran
AUTHOR
Seyed Davar
Siadat
7
Department of Mycobacteriology and Pulmonary Research, Pasteur Institute of Iran, Tehran, Iran
AUTHOR
ORIGINAL_ARTICLE
Evaluation of an Albumin-Binding Domain Protein Fused to Recombinant Human IL-2 and Its Effects on the Bioactivity and Serum Half-Life of the Cytokine
http://ibj.pasteur.ac.ir/article-1-1849-fa.pdf
2016-11-02
77
83
10.18869/acadpub.ibj.21.2.77
Evaluation of an Albumin-Binding Domain Protein Fused to Recombinant Human IL-2 and Its Effects on the Bioactivity and Serum Half-Life of the Cytokine
Background: Cancer immunotherapy is a promising strategy for cancer treatment. In this strategy, the immune system is triggered to destroy cancer cells. IL-2 is an important factor in passive cancer immunotherapy that helps modulating some important immune functions. One of the IL-2 limitations is low serum half-life; therefore, repetitive high doses of the injections are required to maintain effective concentrations. High-dose IL-2 therapy results in severe side effects; thus, improvement of its serum half-life would provide therapeutic benefits. Methods: We have investigated a strategy that is able to utilize an albumin-binding domain (ABD) from streptococcal protein G. In this strategy, the fusion protein ABD-rIL-2 binds to serum albumin, which results in improvement of the IL-2 serum half-life. PET26b+ plasmid was used as an expression vector, which encoded rIL-2 and ABD-rIL-2 both fused to pelB secretion signal under the control of the strong bacteriophage T7 promoter. The constructs were expressed in E. coli Rosetta (DE3) and secreted into the periplasm. Results: The analysis of in vitro bioactivity proved that the fusion of ABD to rIL-2 does not interfere with its bioactivity. ABD-rIL-2 fusion protein indicated higher serum half-life compared to rIL-2, when it was tested in the BALB/c mice. Conclusion: The current study provides an alternative strategy to extend the half-life and improve pharmacokinetic properties of rIL-2 without reducing its bioactivity in vitro.
http://ibj.pasteur.ac.ir/article-1-1849-en.pdf
2016-11-02
77
83
10.18869/acadpub.ibj.21.2.77
Albumin
Albumin-binding domain
Bioactivity
Fusion protein
Interleukin 2
Pharmacokinetics
Serum half-life
Elham
Adabi
1
Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Fateme
Saebi
2
Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Amin
Moradi Hasan-Abad
3
Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
Ladan
Teimoori-Toolabi
4
Molecular Medicine Department, Pasteur Institute of Iran, Tehran, Iran
AUTHOR
Gholam Ali
Kardar
gkardar@tums.ac.ir
5
Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
AUTHOR
ORIGINAL_ARTICLE
Identification and Evaluation of Novel Drug Targets against the Human Fungal Pathogen Aspergillus fumigatus with Elaboration on the Possible Role of RNA-Binding Protein
http://ibj.pasteur.ac.ir/article-1-1896-fa.pdf
2016-12-21
84
93
10.18869/acadpub.ibj.21.2.84
Identification and Evaluation of Novel Drug Targets against the Human Fungal Pathogen Aspergillus fumigatus with Elaboration on the Possible Role of RNA-Binding Protein
Bakground: Aspergillus fumigatus is an airborne opportunistic fungal pathogen that can cause fatal infections in immunocompromised patients. Although the current anti-fungal therapies are relatively efficient, some issues such as drug toxicity, drug interactions, and the emergence of drug-resistant fungi have promoted the intense research toward finding the novel drug targets. Methods: In search of new antifungal drug targets, we have used a bioinformatics approach to identify novel drug targets. We compared the whole proteome of this organism with yeast Saccharomyces cerevisiae to come up with 153 specific proteins. Further screening of these proteins revealed 50 potential molecular targets in A. fumigatus. Amongst them, RNA-binding protein (RBP) was selected for further examination. The aspergillus fumigatus RBP (AfuRBP), as a peptidylprolyl isomerase, was evaluated by homology modeling and bioinformatics tools. RBP-deficient mutant strains of A. fumigatus were generated and characterized. Furthermore, the susceptibility of these strains to known peptidylprolyl isomerase inhibitors was assessed. Results: AfuRBP-deficient mutants demonstrated a normal growth phenotype. MIC assay results using inhibitors of peptidylprolyl isomerase confirmed a higher sensitivity of these mutants compared to the wild type. Conclusion: Our bioinformatics approach revealed a number of fungal-specific proteins that may be considered as new targets for drug discovery purposes. Peptidylprolyl isomerase, as a possible drug target, was evaluated against two potential inhibitors and the promising results were investigated mechanistically. Future studies would confirm the impact of such target on the antifungal discovery investigations.
http://ibj.pasteur.ac.ir/article-1-1896-en.pdf
2016-12-21
84
93
10.18869/acadpub.ibj.21.2.84
Aspergillus fumigatus
RNA-binding protein
Peptidylprolyl isomerase
Juglone
RNA interference
Saeid
Malekzadeh
1
Bioinformatics and Drug Design Unit, Medical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran 1316943551, Iran
AUTHOR
Soroush
Sardari
2
Bioinformatics and Drug Design Unit, Medical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran 1316943551, Iran
AUTHOR
Parisa
Azerang
3
Bioinformatics and Drug Design Unit, Medical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran 1316943551, Iran
AUTHOR
Dorsa
Khorasanizadeh
4
Fungal Biotechnology Unit, Medical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran 1316943551, Iran
AUTHOR
Solmaz
Agha Amiri
5
Fungal Biotechnology Unit, Medical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran 1316943551, Iran
AUTHOR
Mohammad
Azizi
6
Fungal Biotechnology Unit, Medical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran 1316943551, Iran
AUTHOR
Nazanin
Mohajerani
7
Fungal Biotechnology Unit, Medical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran 1316943551, Iran
AUTHOR
Vahid
Khalaj
8
Fungal Biotechnology Unit, Medical Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran 1316943551, Iran
AUTHOR
ORIGINAL_ARTICLE
Phosphorylation of Staphylococcus aureus Protein-Tyrosine Kinase Affects the Function of Glucokinase and Biofilm Formation
http://ibj.pasteur.ac.ir/article-1-1822-fa.pdf
2016-10-01
94
105
10.18869/acadpub.ibj.21.2.94
Phosphorylation of Staphylococcus aureus Protein-Tyrosine Kinase Affects the Function of Glucokinase and Biofilm Formation
Background: When Staphylococcus aureus is grown in the presence of high concentration of external glucose, this sugar is phosphorylated by glucokinase (glkA) to form glucose-6-phosphate. This product subsequently enters into anabolic phase, which favors biofilm formation. The presence of ROK (repressor protein, open reading frame, sugar kinase) motif, phosphate-1 and -2 sites, and tyrosine kinase sites in glkA of S. aureus indicates that phosphorylation must regulate the glkA activity. The aim of the present study was to identify the effect of phosphorylation on the function of S. aureus glkA and biofilm formation. Methods: Pure glkA and protein-tyrosine kinase (BYK) of S. aureus ATCC 12600 were obtained by fractionating the cytosolic fractions of glkA1 and BYK-1 expressing recombinant clones through nickel metal chelate column. The pure glkA was used as a substrate for BYK and the phosphorylation of glkA was confirmed by treating with reagent A and resolving in SDS-PAGE, as well as staining with reagent A. The kinetic parameters of glkA and phosphorylated glkA were determined spectrophotometrically, and in silico tools were used for validation. S. aureus was grown in brain heart infusion broth, which was supplemented with glucose, and then biofilm units were calculated. Results: Fourfold elevated glkA activity was observed upon the phosphorylation by BYK. Protein-protein docking analysis revealed that glkA structure docked close to the adenosine triphosphate-binding site of BYK structure corroborating the kinetic results. Further, S. aureus grown in the presence of elevated glucose concentration exhibited an increase in the rate of biofilm formation. Conclusion: The elevated function of glkA is an essential requirement for increased biofilm units in S. aureus, a key pathogenic factor that helps its survival and spread the infection.
http://ibj.pasteur.ac.ir/article-1-1822-en.pdf
2016-10-01
94
105
10.18869/acadpub.ibj.21.2.94
Glucokinase
Protein-tyrosine kinase
in silico analysis
Dudipeta
Vasu
1
Department of Biotechnology, Sri Venkateswara Institute of Medical Sciences, Tirupati 517 507, Andhra Pradesh, India
AUTHOR
Pasupuleti Santhosh
Kumar
2
Department of Biotechnology, Sri Venkateswara Institute of Medical Sciences, Tirupati 517 507, Andhra Pradesh, India
AUTHOR
Uppu Venkateswara
Prasad
3
Department of Biotechnology, Sri Venkateswara Institute of Medical Sciences, Tirupati 517 507, Andhra Pradesh, India
AUTHOR
Vimjam
Swarupa
4
Department of Biotechnology, Sri Venkateswara Institute of Medical Sciences, Tirupati 517 507, Andhra Pradesh, India
AUTHOR
Sthanikam
Yeswanth
5
Department of Biotechnology, Sri Venkateswara Institute of Medical Sciences, Tirupati 517 507, Andhra Pradesh, India
AUTHOR
Lokanathan
Srikanth
6
Department of Biotechnology, Sri Venkateswara Institute of Medical Sciences, Tirupati 517 507, Andhra Pradesh, India
AUTHOR
Manne Mudhu
Sunitha
7
Department of Biotechnology, Sri Venkateswara Institute of Medical Sciences, Tirupati 517 507, Andhra Pradesh, India
AUTHOR
Abhijith
Choudhary
8
Department of Microbiology, Sri Venkateswara Institute of Medical Sciences, Tirupati 517 507, Andhra Pradesh, India
AUTHOR
Potukuchi Venkata Gurunadha Krishna
Sarma
sarmasvims@gmail.com
9
Department of Biotechnology, Sri Venkateswara Institute of Medical Sciences, Tirupati 517 507, Andhra Pradesh, India
AUTHOR
ORIGINAL_ARTICLE
Investigation of MicroRNA-21 Expression Levels in Serum and Stool as a Potential Non-Invasive Biomarker for Diagnosis of Colorectal Cancer
http://ibj.pasteur.ac.ir/article-1-1760-fa.pdf
2016-07-19
106
113
10.18869/acadpub.ibj.21.2.106
Investigation of MicroRNA-21 Expression Levels in Serum and Stool as a Potential Non-Invasive Biomarker for Diagnosis of Colorectal Cancer
Background: Most cancer studies focus on exploring non-invasive biomarkers for cancer detection. In the present study, we sought to investigate the expression level of microRNA-21 (miR-21), as a potential diagnostic marker, in serum and stool samples from 40 patients with colorectal cancer (CRC) and 40 healthy controls. Methods: Quantitative real-time RT-PCR was applied to determine the relative expression level of miR-21 in serum and stool. At the same time, the sensitivity and specificity of this marker was evaluated by receiver operating characteristic (ROC) curve analysis. Results: miR-21 expression levels of serum and stool were up-regulated 12.1 (P<0.05, 95% CI: 5.774-34.045) and 10.0 (P<0.05, 95% CI: 0.351-16.260) times in CRC patients, respectively, when compared to the control group. The sensitivity and specificity of miR-21 was found to be 86.05% and 72.97%, respectively (an area under the ROC curve [AUC] of 0.783). The stool miR-21 level in CRC patients was much higher than that in the healthy controls, showing a sensitivity of 86.05% and a specificity of 81.08% (AUC: 0.829). The expression level of miR-21 in stool was able to significantly distinguish CRC tumor, node, metastasis stages III-IV from stages I-II, with a sensitivity and specificity of 88.1% and 81.6%, respectively (AUC: 0.872). Conclusion: The results of this study indicated that miR-21 expression levels in serum and stool can be considered as a potential diagnostic biomarker for the diagnosis of CRC patients. However, more studies are required to confirm the validity of miR-21 as a valuable non-invasive diagnostic tool for CRC.
http://ibj.pasteur.ac.ir/article-1-1760-en.pdf
2016-07-19
106
113
10.18869/acadpub.ibj.21.2.106
Serum
Stool
miR-21
Biomarker
Colorectal Cancer (CRC)
Saiyad
Bastaminejad
1
Department of Molecular Medicine and Genetics, Research Center for Molecular Medicine, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran;
AUTHOR
Morovat
Taherikalani
2
Razi Herbal Medicines Research Center, Department of Microbiology, School of Medicine Lorestan University of Medical Sciences, Khorramabad, Iran
AUTHOR
Reza
Ghanbari
3
Digestive Oncology Research Center, Digestive Disease Research Institute, Tehran University of Medical Science, Tehran, Iran
AUTHOR
Akbar
Akbari
4
Abadan School of Medical Sciences, Abadan, Iran
AUTHOR
Nooshin
Shabab
5
Department of Molecular Medicine and Genetics, Research Center for Molecular Medicine, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran;
AUTHOR
Massoud
Saidijam
sjam110@yahoo.com
6
Department of Molecular Medicine and Genetics, Research Center for Molecular Medicine, School of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran;
AUTHOR
ORIGINAL_ARTICLE
Ghrelin Exerts Analgesic Effects through Modulation of IL-10 and TGF-β Levels in a Rat Model of Inflammatory Pain
Background: Ghrelin is a peptide with attenuating effect on inflammatory pain. Both anti- and pro-inflammatory mediators have a role in the nociception and development of pain and hyperalgesia. IL-10 and TGF-β are anti-inflammatory cytokines and inhibit the expression of pro-inflammatory cytokines related to peripheral and central inflammatory pain. In this study, the effects of i.p. injection of ghrelin on the early and the late phases of pain, as well as serum levels of IL-10 and TGF-β, as anti-inflammatory cytokines, were investigated in formalin-induced pain in male rats. Methods: Adult male Wistar rats (n=48) were randomly divided into six groups: control, formalin+saline, ghrelin (40, 80, and 160 μg/kg), and morphine. Ghrelin was administered i.p. 30 min before inducing pain by formalin. Pain induced by intraplantar (i.pl.) injection of 50 µl formalin 5%, and pain behavior was studied for 60 min. Serum IL-10 and TGF-β levels were assessed by ELISA method. Results: The findings of the present study showed that ghrelin with high doses (80 and 160 μg/kg) significantly reduced pain intensity in both the early and the late phases of pain. The serum levels of cytokines, IL-10, and TGF-β1 showed a significant elevation with ghrelin at dose of 160 μg/kg. Conclusion: Ghrelin is effective in reducing the intensity of both the early and the late phases of inflammatory pain. It seems that ghrelin exerts its analgesic effects in part by increasing the serum levels of anti-inflammatory cytokines.
http://ibj.pasteur.ac.ir/article-1-1828-en.pdf
2016-10-05
114
119
10.18869/acadpub.ibj.21.2.114
Pain
Ghrelin
IL-10
TGF-β
Formalin test
Faranak
Azizzadeh
1
Drug Applied Research Center of Tabriz University of Medical Sciences, Tabriz, Iran
AUTHOR
Javad
Mahmoodi
2
Neuroscience Research Center of Tabriz University of Medical Sciences, Tabriz, Iran
AUTHOR
Saeed
Sadigh-Eteghad
3
Neuroscience Research Center of Tabriz University of Medical Sciences, Tabriz, Iran
AUTHOR
Fereshteh
Farajdokht
4
Neuroscience Research Center of Tabriz University of Medical Sciences, Tabriz, Iran
AUTHOR
Gisou
Mohaddes
mohaddesg@tbzmed.ac.ir
5
Neuroscience Research Center of Tabriz University of Medical Sciences, Tabriz, Iran
AUTHOR
SHORT_COMMUNICATION
Association of ABCB1 (C3435T) and ABCC1 (G2012T) Polymorphisms with Clinical Response to Atorvastatin in Iranian Patients with Primary Hyperlipidemia
http://ibj.pasteur.ac.ir/article-1-1718-fa.pdf
2016-05-30
120
125
10.18869/acadpub.ibj.21.2.120
Association of ABCB1 (C3435T) and ABCC1 (G2012T) Polymorphisms with Clinical Response to Atorvastatin in Iranian Patients with Primary Hyperlipidemia
Background: Atorvastatin is prescribed for the primary and the secondary prevention of coronary artery diseases. A wide variation in inter-individual statin response suggests that genetic differences may contribute to this variation. This study investigated the association of ABCB1 (C3435T) and ABCC1 (G2012T) polymorphisms with clinical response to atorvastatin in Iranian primary hyperlipidemic patients. Methods: Individuals (n=179) with primary hypercholesterolemia were enrolled, and peripheral blood samples were collected. Genotyping of two polymorphisms were performed by amplification refractory mutation system PCR. Results: Following four weeks of treatment, a significant reduction of LDL-C was observed in variant groups (CT+TT) of ABCB1 (P=0.018) and wild-type group (GG) of ABCC1 genes (P=0.029). Logistic regression analysis revealed a significant difference between male and female responses to 10 mg/day atorvastatin (P=0.004, odds ratio=0.2, CI 95%=0.06-0.6). Conclusion: Our finding indicated that these polymorphisms may be attributed to LDL-C serum levels in the primary hypercholesterolemia patients receiving atorvastatin.
http://ibj.pasteur.ac.ir/article-1-1718-en.pdf
2016-05-30
120
125
10.18869/acadpub.ibj.21.2.120
Hypercholesterolemia
Statin
Gene polymorphisms
Niusha
Behdad
1
Department of Pharmacotherapy, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Javad
Kojuri
2
Department of Cardiology, Faculty of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Negar
Azarpira
3
Transplant Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Amir
Masoomi
4
Department of Pharmacotherapy, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
Soha
Namazi
snamazi@sums.ac.ir
5
Department of Pharmacotherapy, Faculty of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
AUTHOR
SHORT_COMMUNICATION
The First Report of a 290-bp Deletion in β-Globin Gene in the South of Iran
http://ibj.pasteur.ac.ir/article-1-1661-fa.pdf
2016-03-07
126
128
10.18869/acadpub.ibj.21.2.126
The First Report of a 290-bp Deletion in β-Globin Gene in the South of Iran
Background: β-thalassemia is one of the most widespread disease in the world, including Iran. In this study, we reported, for the first time, A 290-bp β-globin gene deletion in the south of Iran. Methods: Four individuals from three unrelated families with Arabic ethnic background were studied in Khuzestan Province. Red blood cell indices and hemoglobin analysis were carried out according to the standard methods. Genomic DNA was obtained from peripheral blood cells by salting out procedures. β-globin gene amplification, multiplex ligation-dependent probe amplification (MLPA) and DNA sequencing were performed. Results: The PCR followed by sequencing and MLPA test of the β-globin gene confirmed the presence of a 290-bp deletion in the heterozygous form, along with -88C>A mutation. All the individuals had elevated hemoglobin A2 and normal fetal hemoglobin levels. Conclusions: This mutation causes β0-thalassemia and can be highly useful for prenatal diagnosis in compound heterozygous condition with different β-globin gene mutations.
http://ibj.pasteur.ac.ir/article-1-1661-en.pdf
2016-03-07
126
128
10.18869/acadpub.ibj.21.2.126
β-thalassemia
β-globin gene mutation
Iran
Multiplex ligation-dependent probe amplification
Mohammad
Hamid
1
Dept. of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
AUTHOR
Ladan
Dawoody Nejad
2
Dept. of Molecular Medicine, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
AUTHOR
Gholamreza
Shariati
Shariatig@yahoo.com
3
Dept. of Medical Genetic, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
AUTHOR
Hamid
Galehdari
4
Dept. of Medical Genetic, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
AUTHOR
Alihossein
Saberi
5
Dept. of Medical Genetic, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
AUTHOR
Marziye
Mohammadi-Anaei
6
Narges Medical Genetics and Prenatal Diagnosis Laboratory, No. 18, East Mihan Ave., Kianpars, Ahvaz, Iran
AUTHOR